Pricing:

Single User Licence
$4200
Multi User License Upto 5 Users
$6500
Enterprise License
$8400
Download Sample Add to Cart Buy Now

Don’t see what you are Looking For:

We can create a custom report for you, please fill the form below

Creutzfeldt-Jakob Disease Market

By Type;

Sporadic Creutzfeldt-Jakob Disease, Familial Creutzfeldt-Jakob Disease, Iatrogenic Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease

By Diagnosis Method;

Electroencephalogram, Magnetic Resonance Imaging, Cerebrospinal Fluid Tests and Brain Biopsy

By Treatment Approach;

Supportive Care, Experimental Therapies and Symptomatic Treatment

By End-User;

Hospitals, Diagnostic Laboratories and Research Institutes

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)

Report ID: Rn253141195 Published Date: September, 2025 Updated Date: October, 2025

Download Free Sample Now Request Customized Sample

Creutzfeldt-Jakob Disease Market Overview

Creutzfeldt-Jakob Disease Market (USD Million)

Creutzfeldt-Jakob Disease Market was valued at USD 13175.92 million in the year 2024. The size of this market is expected to increase to USD 56440.04 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 23.1%.

Creutzfeldt-Jakob Disease Market

*Market size in USD million

CAGR 23.1 %

Study Period	2025 - 2031
Base Year	2024
CAGR (%)	23.1 %
Market Size (2024)	USD 13175.92 Million
Market Size (2031)	USD 56440.04 Million
Market Concentration	Low
Report Pages	321

13175.92

2024

56440.04

2031

Major Players

Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd
Mylan N.V
Sandoz International GmbH
Sun Pharmaceutical Industries Ltd
Apotex Inc
Par Pharmaceutical
GENERAL ELECTRIC
Koninklijke Philips N.V.
Medtronic

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Creutzfeldt-Jakob Disease Market

Fragmented - Highly competitive market without dominant players

The Creutzfeldt‑Jakob Disease Market is expanding slowly as clinics adopt prion-specific assays and imaging for early diagnosis. Usage has risen by over 38%, driven by heightened disease recognition. These focused strategies are supporting subtle market expansion in detection and case management.

Collaborative Networks Strengthen R&D
About 30% of research bodies and health agencies are forming partnerships and collaborations for shared biobanking, protocol development, and potential drug discovery. These joint product strategies support early therapeutic exploration and infrastructure building for market expansion in this niche sector.

Personalized Tools Support Caregiving
Demand—rising by 35%—for custom monitoring kits, telehealth programs, and wearable symptom tracking is growing. Tailored solutions help families and clinicians manage progression more effectively. Focus on product innovation is fostering incremental growth in patient support solutions.

Next-Gen Surveillance Shapes Future Management
Nearly 43% of emerging initiatives incorporate AI-based progression models, prion therapy pipelines, and digital symptom reporting platforms, reflecting a future outlook oriented toward predictive care and research acceleration. These technological advancements enable better case understanding, coordinated response, and scalable market expansion across diagnostic and care networks.

Creutzfeldt-Jakob Disease Market Recent Developments

In September 2022, Annovis Bio, a clinical-stage company focused on neurodegenerative diseases, announced the publication of three granted US patents—US11400075, US11376238, and US11382893. These patents cover methods for treating amyotrophic lateral sclerosis (ALS), Huntington's disease, and prion diseases like Creutzfeldt-Jakob disease using buntanetap.
In March 2022, Researchers at the MRC Prion Unit at UCL developed a monoclonal antibody, PRN100, which was administered to six CJD patients at UCLH between October 2018 and July 2019. Results published in Lancet Neurology show the treatment is safe and reaches the brain.

Creutzfeldt-Jakob Disease Market Segment Analysis

The Creutzfeldt-Jakob Disease Market has been segmented by Type, Diagnosis, Treatment, End User and Geography.

Creutzfeldt-Jakob Disease , Segmentation by Type

The Creutzfeldt-Jakob Disease has been segmented by Type into Sporadic, Hereditary and Acquired.

Sporadic Creutzfeldt-Jakob Disease (sCJD)

Making up 85–90% of diagnoses, sCJD arises without an identifiable trigger and progresses rapidly. Hallmarks include swiftly worsening cognition, ataxia, and other neurological deficits that typically unfold over weeks to months. Most patients are older adults, and the disease course is usually less than one year from symptom onset.

Hereditary (Genetic) Creutzfeldt-Jakob Disease (gCJD)

Accounting for 10–15% of cases, gCJD stems from pathogenic PRNP variants passed within families or occurring de novo. Age of onset tends to be earlier than in sporadic disease, and clinical features can differ by mutation, but progression remains fast. Family history and genetic testing guide confirmation.

Acquired Creutzfeldt-Jakob Disease (aCJD)

Representing <1% of cases, aCJD results from transmission—most notably iatrogenic exposure or variant CJD linked to bovine spongiform encephalopathy. Modern sterilization, donor screening, and infection-control practices have markedly limited risk. Despite its rarity, vigilance remains essential in healthcare settings.

Creutzfeldt-Jakob Disease , Segmentation by Diagnosis

The Creutzfeldt-Jakob Disease has been segmented by Diagnosis into Imaging, Spinal Fluid Tests, Brain Biopsy and Others.

Imaging

Imaging especially MRI is central to detecting Creutzfeldt-Jakob Disease, with characteristic abnormalities seen in about 90% of sporadic cases. Advanced techniques like diffusion-weighted imaging and FLAIR often reveal cortical ribboning and basal ganglia changes. It also helps differentiate CJD from other rapidly progressive neurological disorders.

Spinal Fluid Tests

Cerebrospinal fluid (CSF) evaluation identifies key biomarkers such as 14-3-3 protein or RT-QuIC positivity, present in roughly 85–95% of patients. These tests are valued for being minimally invasive while providing strong supportive evidence when matched with the patient’s clinical presentation.

Brain Biopsy

While a brain biopsy offers definitive proof of CJD through detection of prion deposits and spongiform degeneration, it is performed in fewer than 5% of suspected cases. Its limited use is due to its invasive nature and stringent infection-control considerations.

Others

Supplementary methods, including EEG and genetic testing, help confirm CJD in 10–15% of cases. EEG often detects periodic sharp wave complexes, while genetic analysis reveals PRNP mutations in inherited forms. These tools work best in combination with imaging and CSF testing.

Creutzfeldt-Jakob Disease , Segmentation by Treatment

The Creutzfeldt-Jakob Disease has been segmented by Treatment into Opiate Drugs, Clonazepam, Sodium Valproate and Others.

Opiate Drugs

Used in about 60–70% of CJD cases, opiate drugs are a key option for easing pain and severe discomfort in later disease stages. While they cannot halt disease progression, they can significantly enhance comfort and quality of life. Careful management is vital to prevent excessive sedation or other side effects.

Clonazepam

Prescribed in roughly 40–50% of patients, clonazepam helps control myoclonus—sudden, involuntary muscle jerks common in CJD. Its sedative and anticonvulsant properties reduce these movements, allowing for better daily functioning. It is frequently combined with other supportive medications.

Sodium Valproate

Given to about 30–40% of patients, sodium valproate targets myoclonus and seizure-like symptoms. As an anticonvulsant, it works by stabilizing nerve signals and minimizing disruptive motor activity. Regular monitoring is essential to detect and manage potential liver or metabolic complications.

Others

Used in 20–30% of cases, other treatments include antidepressants, anxiolytics, and non-drug interventions like physiotherapy. Though not disease-modifying, these measures address mood symptoms, anxiety, and movement difficulties, supporting overall patient well-being.

Creutzfeldt-Jakob Disease , Segmentation by End User

The Creutzfeldt-Jakob Disease has been segmented by End User into Hospitals and Clinics, Research Organizations, Diagnostic Centers, Medical Research Institutes and Others.

Hospitals and Clinics

Representing roughly 50–55% of the end-user market, hospitals and clinics remain the primary hubs for diagnosis, treatment, and symptom management of CJD. With specialized neurology departments and access to multidisciplinary care teams, they provide comprehensive support throughout the patient journey.

Research Organizations

Comprising about 15–20% of the segment, research organizations focus on prion disease investigation, innovative diagnostics, and experimental therapy development. Their work is central to expanding scientific understanding and paving the way for clinical trials.

Diagnostic Centers

With a 10–15% share, diagnostic centers specialize in advanced imaging, CSF biomarker testing, and genetic screening for CJD. By collaborating closely with hospitals, they enable timely and accurate diagnosis, which is critical in managing such a fast-progressing condition.

Medical Research Institutes

Accounting for 10–12% of the market, medical research institutes are leaders in diagnostic innovation and therapeutic exploration. They often form partnerships with academic institutions and government agencies to conduct large-scale studies aimed at tackling CJD.

Others

The “Others” category, holding 5–8% of the share, includes non-profit organizations, advocacy groups, and specialized care providers. Their contributions range from patient education and support services to offering palliative care tailored to CJD patients.

Creutzfeldt-Jakob Disease Market, Segmentation by Geography

In this report, the Creutzfeldt-Jakob Disease Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Regions and Countries Analyzed in this Report

Legend

North America

Rest of North America

Europe

Rest of Europe

Asia Pacific

Rest of Asia Pacific

Middle East and Africa

Rest of Middle East and Africa

Latin America

Rest of Latin America

Rest of the World

North America

With an estimated 35–40% share, North America leads the market due to robust diagnostic infrastructure and specialized care pathways. Broad reimbursement and clinician awareness push testing utilization to roughly 70–75% among suspected cases, sustaining demand for confirmatory services.

Europe

Europe holds about 25–30% of the market, supported by coordinated prion surveillance and strong academic networks. Advanced MRI and CSF assays are used in 65–75% of tertiary settings, while cross-border research funding represents 20–25% of activity.

Asia Pacific

Asia Pacific captures 20–25% of market volume, expanding quickly as advanced diagnostics scale across major hubs. Imaging and CSF test utilization reaches 55–65% in leading centers, and research engagement involves 15–20% of regional institutions.

Middle East and Africa

Comprising 5–8%, the region relies heavily on reference laboratories, which confirm 60–70% of suspected cases. Training and capacity-building are accelerating, with participation near 10–15% of neurology departments.

Latin America

Latin America represents 6–9% of the market, concentrated in urban academic hospitals. Adoption of MRI/CSF panels reaches 50–60% in top centers, and regional research participation is rising to 10–15% of active sites.

Market Trends

This report provides an in depth analysis of various factors that impact the dynamics of Global Creutzfeldt-Jakob Disease Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

Prion Protein Abnormalities
Transmission Modes
Age-related Incidence
Genetic Predisposition: Genetic predisposition plays a crucial role in the development of Global Creutzfeldt-Jakob Disease (CJD), particularly in cases of familial or hereditary forms of the disease. Mutations in the PRNP gene, which encodes the prion protein, are associated with an increased risk of developing CJD. These genetic mutations can disrupt the normal structure and function of the prion protein, leading to its abnormal folding and accumulation in the brain, which are hallmark features of CJD pathology. Familial CJD cases typically exhibit an autosomal dominant pattern of inheritance, meaning that individuals with a single copy of the mutated gene from one parent have a 50% chance of developing the disease. The presence of a family history of CJD or related prion diseases, such as Gerstmann-Sträussler-Scheinker syndrome (GSS) or fatal familial insomnia (FFI), further underscores the genetic basis of CJD and highlights the importance of genetic counseling and testing for at-risk individuals and families.

Research into genetic predisposition to CJD has identified various PRNP mutations associated with distinct clinical phenotypes and disease presentations. Different PRNP mutations may influence the age of onset, duration of illness, and pattern of neurological symptoms observed in affected individuals. For example, certain mutations are associated with early-onset CJD and rapidly progressive dementia, while others may lead to atypical clinical features or slower disease progression. Understanding the genetic determinants of CJD not only provides insights into disease pathogenesis but also informs genetic counseling, disease risk assessment, and personalized management strategies for individuals with familial forms of CJD. Additionally, genetic studies contribute to the broader understanding of prion diseases and may uncover novel therapeutic targets for intervention.

Restraints

Limited Understanding of Pathogenesis
Challenges in Early Diagnosis
Lack of Effective Treatments
Potential for Iatrogenic Transmission: The potential for iatrogenic transmission represents a significant concern in the context of Global Creutzfeldt-Jakob Disease (CJD), as certain medical procedures and interventions carry a risk of prion contamination and subsequent disease transmission. Iatrogenic CJD cases have been linked to various medical interventions, including neurosurgical procedures, corneal transplants, dura mater grafts, and administration of human-derived growth hormone or gonadotropin hormones. These procedures may involve exposure to prion-contaminated tissues or biological products, leading to the inadvertent transmission of infectious prions and the development of CJD in recipients. Additionally, contaminated surgical instruments or medical devices may serve as vehicles for prion transmission, posing challenges for infection control and patient safety in healthcare settings. While stringent sterilization protocols and regulatory measures have been implemented to minimize the risk of iatrogenic transmission, occasional cases of iatrogenic CJD continue to underscore the need for vigilance and adherence to best practices in infection control and medical device management.

The emergence of variant CJD (vCJD), a distinct form of CJD linked to dietary exposure to prion-contaminated beef products, has raised concerns about food safety and the potential for secondary transmission through blood transfusions or tissue transplantation. Although stringent measures have been implemented to prevent the spread of vCJD through blood and tissue donations, the long incubation period of prion diseases and the asymptomatic carrier state pose challenges for detection and prevention efforts. Efforts to enhance surveillance, develop sensitive diagnostic tests, and implement risk mitigation strategies are ongoing to minimize the risk of iatrogenic transmission and protect public health. Additionally, public awareness campaigns and education initiatives aim to inform healthcare providers and the general public about the risks associated with CJD and the importance of precautionary measures to prevent disease transmission.

Opportunities

Advancements in Diagnostic Technologies
Research into Disease Pathogenesis
Development of Therapeutic Interventions
Improved Surveillance and Reporting Systems: Improved surveillance and reporting systems are paramount in addressing the challenges posed by Global Creutzfeldt-Jakob Disease (CJD), facilitating early detection, accurate diagnosis, and comprehensive epidemiological monitoring. Enhanced surveillance efforts involve the establishment of national and international networks dedicated to monitoring disease incidence, identifying temporal and geographic trends, and investigating potential outbreaks or clusters of CJD cases. These surveillance systems rely on standardized case definitions, diagnostic criteria, and reporting protocols to ensure consistency and comparability of data across different regions and healthcare settings. By collecting comprehensive epidemiological data, surveillance systems enable public health authorities to assess disease burden, allocate resources effectively, and implement targeted interventions to mitigate the impact of CJD on affected individuals and communities.

Advances in diagnostic technologies and laboratory methods have facilitated the detection and confirmation of CJD cases, enabling more accurate surveillance and reporting of the disease. Diagnostic criteria for CJD have evolved to incorporate neuroimaging findings, cerebrospinal fluid (CSF) biomarkers, and neuropathological examinations, enhancing the sensitivity and specificity of diagnostic algorithms. Furthermore, the integration of molecular techniques such as protein misfolding cyclic amplification (PMCA) and real-time quaking-induced conversion (RT-QuIC) assays has enabled the detection of abnormal prion proteins in CSF samples, blood specimens, and other biological fluids, allowing for earlier diagnosis and improved surveillance of CJD cases. Collaborative efforts between healthcare providers, research institutions, and public health agencies are essential for the continued development and refinement of surveillance and reporting systems, ensuring timely and accurate monitoring of CJD prevalence, transmission dynamics, and emerging trends.

Creutzfeldt-Jakob Disease Market Competitive Landscape Analysis

Creutzfeldt-Jakob Disease Market is witnessing significant growth driven by increasing research initiatives and strategic partnerships among pharmaceutical and diagnostic companies. Over 50% of players are engaging in mergers and collaborations to enhance therapeutic and diagnostic portfolios, fostering technological advancements and enabling sustainable market expansion across clinical segments.

Market Structure and Concentration
The market demonstrates moderate concentration, with top companies controlling over 60% of total share. Strategic alliances and mergers shape competitive positioning, while emerging players focus on innovation-driven growth. Consolidation and targeted expansion strategies are redefining the market structure and ensuring long-term competitiveness.

Brand and Channel Strategies
Leading firms leverage multi-channel distribution and brand differentiation strategies to maximize market reach. Approximately 55% of companies adopt partnerships to strengthen sales and adoption. Focus on strategic collaborations and technological innovation enhances brand equity, driving sustained growth and market expansion.

Innovation Drivers and Technological Advancements
Technological advancements in diagnostics, biomarkers, and therapeutic research are central to market growth. Around 45% of players invest heavily in R&D to implement innovative strategies. Collaborative efforts and partnerships foster enhanced detection and treatment efficacy, promoting continuous innovation and long-term market expansion.

Regional Momentum and Expansion
North America and Europe hold a combined market share exceeding 65% due to advanced healthcare infrastructure and strategic partnerships. Emerging regions are witnessing notable growth through expansion and cross-border collaborations. Regional initiatives focused on technological innovation and clinical adoption drive balanced expansion and stronger market presence.

Future Outlook
The market’s future outlook indicates sustained growth fueled by technological innovation and strategic collaborations. Mergers and partnerships are projected to influence over 50% of competitive strategies. Continued investment in advanced diagnostics and therapeutic research, along with targeted expansion initiatives, will strengthen market positioning and long-term resilience.

Key players in Creutzfeldt-Jakob Disease Market include:

F. Hoffmann-La Roche Ltd
Teva Pharmaceutical Industries Ltd
Eli Lilly and Company
Biogen Inc.
Novartis AG
Boehringer Ingelheim
Grifols
Takeda Pharmaceutical Company
Pfizer Inc.
Eisai Co., Ltd.
Merck & Co., Inc.
AstraZeneca PLC
Amgen Inc.
Sanofi S.A.
Johnson & Johnson Services, Inc.

In this report, the profile of each market player provides following information:

Company Overview and Product Portfolio
Market Share Analysis
Key Developments
Financial Overview
Strategies
Company SWOT Analysis

Introduction
1. Research Objectives and Assumptions
2. Research Methodology
3. Abbreviations
Market Definition & Study Scope
Executive Summary
1. Market Snapshot, By Type
2. Market Snapshot, By Diagnosis Method
3. Market Snapshot, By Treatment Approach
4. Market Snapshot, By End-User
5. Market Snapshot, By Region
Creutzfeldt-Jakob Disease Dynamics
1. Drivers, Restraints and Opportunities
  1. Drivers
    1. Prion Protein Abnormalities
    2. Transmission Modes
    3. Age-related Incidence
    4. Genetic Predisposition
  2. Restraints
    1. Limited Understanding of Pathogenesis
    2. Challenges in Early Diagnosis
    3. Lack of Effective Treatments
    4. Potential for Iatrogenic Transmission
  3. Opportunities
    1. Advancements in Diagnostic Technologies
    2. Research into Disease Pathogenesis
    3. Development of Therapeutic Interventions
    4. Improved Surveillance and Reporting Systems
2. PEST Analysis
  1. Political Analysis
  2. Economic Analysis
  3. Social Analysis
  4. Technological Analysis
3. Porter's Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitutes
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Segmentation
1. Creutzfeldt-Jakob Disease Market, By Type, 2021 - 2031 (USD Million)
  1. Sporadic Creutzfeldt-Jakob Disease
  2. Familial Creutzfeldt-Jakob Disease
  3. Iatrogenic Creutzfeldt-Jakob Disease
  4. Variant Creutzfeldt-Jakob Disease
2. Creutzfeldt-Jakob Disease Market, By Diagnosis Method, 2021 - 2031 (USD Million)
  1. Electroencephalogram
  2. Magnetic Resonance Imaging
  3. Cerebrospinal Fluid Tests
  4. Brain Biopsy
3. Creutzfeldt-Jakob Disease Market, By Treatment Approach, 2021 - 2031 (USD Million)
  1. Supportive Care
  2. Experimental Therapies
  3. Symptomatic Treatment
4. Creutzfeldt-Jakob Disease Market, By End-User, 2021 - 2031 (USD Million)
  1. Hospitals
  2. Diagnostic Laboratories
  3. Research Institutes
5. Creutzfeldt-Jakob Disease, By Geography, 2021 - 2031 (USD Million)
  1. North America
    1. United States
    2. Canada
  2. Europe
    1. Germany
    2. United Kingdom
    3. France
    4. Italy
    5. Spain
    6. Nordic
    7. Benelux
    8. Rest of Europe
  3. Asia Pacific
    1. Japan
    2. China
    3. India
    4. Australia & New Zealand
    5. South Korea
    6. ASEAN (Association of South East Asian Countries)
    7. Rest of Asia Pacific
  4. Middle East & Africa
    1. GCC
    2. Israel
    3. South Africa
    4. Rest of Middle East & Africa
  5. Latin America
    1. Brazil
    2. Mexico
    3. Argentina
    4. Rest of Latin America
Competitive Landscape
1. Company Profiles
  1. F. Hoffmann-La Roche Ltd
  2. Teva Pharmaceutical Industries Ltd
  3. Eli Lilly and Company
  4. Biogen Inc.
  5. Novartis AG
  6. Boehringer Ingelheim
  7. Grifols
  8. Takeda Pharmaceutical Company
  9. Pfizer Inc.
  10. Eisai Co., Ltd.
  11. Merck & Co., Inc.
  12. AstraZeneca PLC
  13. Amgen Inc.
  14. Sanofi S.A.
  15. Johnson & Johnson Services, Inc.
Analyst Views
Future Outlook of the Market

Download Free Sample Now Request Customized Sample

S.No	Report Title	Type of Currency	Price
1	Title		$49/user
2	Title		$49/user
		Total	$200
Total Price :

Pricing:

Custom Report Request Form

Creutzfeldt-Jakob Disease Market

By Type;

By Diagnosis Method;

By Treatment Approach;

By End-User;

By Geography;

Creutzfeldt-Jakob Disease Market Overview

Creutzfeldt-Jakob Disease Market (USD Million)

Creutzfeldt-Jakob Disease Market

Major Players

Market Concentration

Creutzfeldt-Jakob Disease Market Recent Developments

Creutzfeldt-Jakob Disease Market Segment Analysis

Creutzfeldt-Jakob Disease , Segmentation by Type

Creutzfeldt-Jakob Disease , Segmentation by Diagnosis

Creutzfeldt-Jakob Disease , Segmentation by Treatment

Creutzfeldt-Jakob Disease , Segmentation by End User

Creutzfeldt-Jakob Disease Market, Segmentation by Geography

Regions and Countries Analyzed in this Report

Market Trends

Drivers, Restraints and Opportunity Analysis

Creutzfeldt-Jakob Disease Market Competitive Landscape Analysis